Denali 制药
DNLI
17.61
-0.73
-3.98%
Denali 制药
US · DNLI
#2454 按市值排名
上市于 2017
17.61
-0.73
-3.98%
实时 - 追踪5344个代码 - 心跳于463秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例下降了4.3个百分点。
机构持股
- 机构持股比例
- 99.03% -4.34pp
- 机构数量
- 351 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund75.71%
Hedge Fund10.10%
VC/PE Fund7.83%
Individual/Insider2.97%
Public Company2.37%
Sovereign Wealth Fund1.78%
Private Company0.57%
Government Pension Fund0.52%
Insurance Company0.13%
主要股东 截至 2026-06-30
T. Rowe Price Group, Inc.
12.08% · 19.32M 股
BlackRock
8.77% · 14.03M 股
Baillie Gifford
7.48% · 11.96M 股
Vanguard Capital Management, LLC
4.55% · 7.27M 股
State Street Global Advisors
4.41% · 7.05M 股
Temasek Holdings
4.39% · 7.01M 股
Vanguard Portfolio Management, LLC
4.05% · 6.48M 股
UBS Asset Management
3.93% · 6.28M 股
FMR
2.83% · 4.52M 股
Geode Capital Management, LLC
2.49% · 3.97M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 31次买入 · 17次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Ryan Watts | Chief Executive Officer | 1.40% |
| Steve Krognes | Director | 0.51% |
| Alexander Schuth | Co-Founder, CFO, COO & Secretary | 0.42% |
| Jay Flatley | Independent Director | 0.22% |
| Julian Baker | Independent Chairperson | 0.21% |
| Peter Chin | Senior Vice President of Late Clinical Development & Medical Affairs | 0.13% |
| David Schenkein | Independent Director | 0.05% |
| Peter Klein | Independent Director | 0.02% |
| Jennifer Cook | Independent Director | 0.02% |
| Nancy Thornberry | Independent Director | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-03 | Peter Chin | Senior Vice President of Late Clinical Development & Medical Affairs | Open Market Disposition | -1,654 | $22.29 |
| 2026-09-01 | Nancy Thornberry | Independent Director | Automatic Disposition | -11,439 | $22.85–23.74 |
| 2026-08-31 | Alexander Schuth | Co-Founder, CFO, COO & Secretary | Automatic Disposition | -2,768 | $23.44 |
| 2026-08-11 | Ryan Watts | Chief Executive Officer | Other Disposition | -32,220 | -- |
| 2026-08-10 | Alexander Schuth | Co-Founder, CFO, COO & Secretary | Open Market Disposition | -2,857 | $25.07 |
| 2026-06-02 | Jay Flatley | Independent Director | Other Acquisition | +6,408 | -- |
| 2026-06-02 | Jay Flatley | Independent Director | Other Derivative Acquisition | +19,226 | $19.66 |
| 2026-06-02 | Julian Baker | Independent Chairperson | Other Acquisition | +12,816 | -- |
| 2026-06-02 | Julian Baker | Independent Chairperson | Other Derivative Acquisition | +19,226 | $19.66 |
| 2026-06-02 | David Schenkein | Independent Director | Other Acquisition | +6,408 | -- |
| 2026-06-02 | David Schenkein | Independent Director | Other Derivative Acquisition | +19,226 | $19.66 |
| 2026-06-02 | Peter Klein | Independent Director | Other Acquisition | +6,408 | -- |
| 2026-06-02 | Peter Klein | Independent Director | Other Derivative Acquisition | +19,226 | $19.66 |
| 2026-06-02 | Jennifer Cook | Independent Director | Other Acquisition | +6,408 | -- |
| 2026-06-02 | Jennifer Cook | Independent Director | Other Derivative Acquisition | +19,226 | $19.66 |
| 2026-06-02 | Timothy Van Hauwermeiren | -- | Other Acquisition | +6,408 | -- |
| 2026-06-02 | Timothy Van Hauwermeiren | -- | Other Derivative Acquisition | +19,226 | $19.66 |
| 2026-06-02 | Steve Krognes | Director | Other Acquisition | +6,408 | -- |
| 2026-06-02 | Steve Krognes | Director | Other Derivative Acquisition | +19,226 | $19.66 |
| 2026-06-02 | Nancy Thornberry | Independent Director | Other Acquisition | +6,408 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Denali 制药 讨论区 0 条评论